Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response
Both HP and HPy combined with chemotherapy can be considered as optional NAT regimens for HER2-positive BC. The nomogram incorporating common clinical indicators provides a basis for clinicians to predict NAT efficacy at an earlier stage.
Authors
- Zihao Bai (ORCID: https://orcid.org/0000-0001-7573-3127)
- Lijia Wang (ORCID: https://orcid.org/0000-0002-4264-8150)
- Cuizhi Geng (ORCID: https://orcid.org/0000-0001-5541-5412)
- Haoqi Wang (ORCID: https://orcid.org/0000-0002-9012-5370)
- Shan Gao (ORCID: https://orcid.org/0000-0003-3104-2425)
Institutions
- Hebei Medical University (CN)
- Hospital of Hebei Province (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-17
- DOI
- https://doi.org/10.3389/fonc.2025.1673810
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00